Net clinical benefit of postdischarge extended thromboprophylaxis in hospitalized medical patients in the MAGELLAN trial from identifying a low-bleeding-risk group (excluding 5 key bleeding-risk factors) and a high-VTE-risk group (utilizing an IMPROVE VTE score of ≥4 or a score of 2 or 3 and elevated DD >2 times ULN).

ARR, absolute risk reduction; ISTH, International Society on Thrombosis and Haemostasis; RRR, relative risk reduction. Reproduced with permission from Spyropoulos et al.²³